Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 19Active not recruiting 8Completed 6Withdrawn 3Not yet recruiting 3Terminated 2Suspended 2Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Gastrointestinal 4Lymphoid 3Genitourinary 3Tumor-Agnostic 2Myeloid 2CNS 2Breast 2Thoracic 1Sarcoma 1Gynecologic 1Classical hematology 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Specimen Handling 3venetoclax 2Biopsy 2vactosertib 1regorafenib 1iadademstat 1fludarabine phosphate 1fludarabine 1eltrombopag 1decitabine and cedazuridine drug combination 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1X-Rays 1TAK-243 1Photons 1Melphalan 1KB004 1Interleukin-2 1IL32 protein, human 1Genetic Testing 1Cyclophosphamide 1CYC065 1CA-4948 1Azacitidine 1Ascorbic Acid 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Biopsy × Myeloid × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡